[The role of pronoran in the therapy of late stage of Parkinson's disease].
Pilipovich
A A
AA
Golubev
V L
VL
D018491:Dopamine Agonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010891:Piribedil / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D050637:Receptors, Dopamine D3 / Q000187:drug effects*; D017661:Receptors, Presynaptic / Q000187:drug effects*
D018491:Dopamine Agonists; D018341:Receptors, Adrenergic, alpha-2; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D017661:Receptors, Presynaptic; D010891:Piribedil